切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2013, Vol. 02 ›› Issue (05): 298 -301. doi: 10.3877/cma.j.issn.2095-3232.2013.05.006

所属专题: 文献

临床研究

术后早期肠内营养在肝细胞肝癌半肝切除患者中的应用价值
商昌珍1, 张磊1,(), 余达成1, 曹君1, 陈亚进1   
  1. 1. 510120 广州,中山大学孙逸仙纪念医院肝胆胰外科
  • 收稿日期:2013-06-12 出版日期:2013-10-10
  • 通信作者: 张磊
  • 基金资助:
    广东省科技计划项目(2012B031800378); 广东省自然科学基金(S2012010009741)

Application value of early-stage enteral nutritional support in patients with hepatocellular carcinoma after hemihepatectomy

Chang-zhen SHANG1, Lei ZHANG1,(), Da-cheng YU1, Jun CAO1, Ya-jin CHEN1   

  1. 1. Department of Hepatopancreatobiliary Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510120, China
  • Received:2013-06-12 Published:2013-10-10
  • Corresponding author: Lei ZHANG
  • About author:
    Corresponding author: ZHANG Lei, Email:
目的

探讨术后早期肠内营养在肝细胞肝癌(肝癌)半肝切除患者中的应用价值。

方法

本前瞻性研究对象为2010年10月至2012年9月在中山大学孙逸仙纪念医院肝胆胰外科行半肝切除术的67例肝癌患者。按照随机数字表法将患者分为肠内营养组和静脉营养组。肠内营养组32例,其中男17例,女15例;年龄(48±13)岁。静脉营养组35例,其中男22例,女13例;年龄(51±10)岁。所有患者均签署知情同意书,符合医学伦理学规定。两组患者均行标准解剖性半肝切除术,术后24 h拔除胃管,并根据具体病情进行护肝、补充人血白蛋白等常规处理。肠内营养组患者术后24 h开始给予安素营养液口服,维持至术后7 d。静脉营养组患者术后24 h内即开始给予静脉营养,维持7 d。观察两组患者围手术期丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、白蛋白(ALB)的变化,了解术后人血白蛋白应用情况、胃肠道功能恢复时间和胃肠道不良反应发生情况,统计住院时间和住院费用。两组患者计量资料的比较采用t检验或Wilcoxon秩和检验。

结果

肠内营养组术前ALT(33±17)U/L,AST(35±19)U/L,ALB(36±1)g/L;静脉营养组术前ALT(34±14)U/L,AST(32±18)U/L,ALB(37±2)g/L,两组比较差异无统计学意义(t=0.264,0.664,1.618;P>0.05)。肠内营养组术后3 d的ALT、AST、ALB分别为(153±57)U/L、(108±46)U/L、(32±4)g/L,静脉营养组分别为(149±62)U/L、(104±45)U/L、(31±5)g/L;肠内营养组术后7 d的ALT、AST、ALB分别为(63±38)U/L、(65±44)U/L、(37±3)g/L,静脉营养组分别为(68±32)U/L、(61±39)U/L、(35±5)g/L;两组术后3 d和7 d的ALT、AST、ALB比较差异无统计学意义(t=0.274,0.360,0.898和-0.584,0.394,2.004;P>0.05)。肠内营养组术后静脉补充人血白蛋白总量为(70±25)g,静脉营养组为(90±35)g,肠内营养组人血白蛋白应用总量明显少于静脉营养组(t=-2.708,P<0.05)。肠内营养组术后胃肠道功能恢复时间为(46±13)h,静脉营养组为(66±15)h,肠内营养组术后胃肠道功能恢复时间明显短于静脉营养组(t=-5.807,P<0.05)。肠内营养组患者发生腹胀、腹泻3例,静脉营养组发生腹胀、腹泻2例。肠内营养组术后住院时间为(18±12)d,静脉营养组为(20±14)d,差异无统计学意义(t=-0.625,P>0.05)。肠内营养组和静脉营养组的总住院费用中位数分别为5.3(4.5~7.2)、5.9(5.1~7.9)万元,肠内营养组明显少于静脉营养组(Z=-2.34,P<0.05)。

结论

早期肠内营养有利于肝癌半肝切除术后患者的胃肠道功能恢复,同时降低了住院费用。

Objective

To investigate the application value of early-stage enteral nutritional support in patients with hepatocellular carcinoma (HCC) after hemihepatectomy.

Methods

Sixty-seven HCC patients who underwent hemihepatectomy from October 2010 to December 2012 in Department of Hepatopancreatobiliary Surgery, Sun Yat-sen Memorial Hospital of Sun Yat-sen University were enrolled in this prospective study. The patients were randomly divided into two groups using random digit table: the early enteral nutrition (EEN) group [n=32, 17 males, 15 females, mean age of (48±13) years old] and the parenteral nutrition (PN) group [n=35, 22 males, 13 females, mean age of (51±10) years old]. The informed consents of all patients were obtained and the ethical committee approval was received. Patients in both groups received standard anatomical hemihepatectomy and gastric tubes were withdrawn 24 h after operation. Routine treatments such as liver protection drugs, human albumin and so on were given to the patients according to the specific condition. Patients in EEN group were given Ensure nutrient solution orally from 24 h till 7 d after operation. Patients in PN group were given intravenous nutrition from 24 h till 7 d after operation. The changes of perioperative levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and albumin (ALB) of patients in two groups were observed. The application of human albumin, the length of gastrointestinal function recovery and adverse reactions of gastrointestine after operation were observed and the length of hospital stay and hospitalization cost were calculated. The measurement data between two groups was compared using t test or Wilcoxon rank sum test.

Results

In EEN group, the preoperative level of ALT was (33±17)U/L, AST was (35±19)U/L, ALB was (36±1)g/L. In PN group, the preoperative level of ALT was (34±14)U/L, AST was (32±18)U/L, ALB was (37±2)g/L. There was no significant difference between two groups (t=0.264, 0.664, 1.618; P>0.05). In EEN group, the levels of ALT, AST, ALB on the 3rd day after operation were (153±57)U/L, (108±46)U/L, (32±4)g/L respectively. In PN group, the levels of ALT, AST, ALB on the 3rd day after operation were (149±62)U/L, (104±45)U/L, (31±5)g/L respectively. In EEN group, the levels of ALT, AST, ALB on the 7th day after operation were (63±38)U/L, (65±44)U/L, (37±3)g/L respectively. In PN group, the levels of ALT, AST, ALB on the 7th day after operation were (68±32)U/L, (61±39)U/L, (35±5)g/L respectively. There was no significant difference in the levels of ALT, AST, ALB on the 3rd day and the 7th day after operation between two groups (t=0.274, 0.360, 0.898 and-0.584, 0.394, 2.004; P>0.05). The total volume of intravenous human albumin given to the patients after operation in EEN group was significantly less than that in PN group [(70±25)g vs. (90±35)g; t=-2.708, P<0.05]. The length of postoperative gastrointestinal function recovery in EEN group was significantly shorter than that in PN group [(46±13)h vs. (66±15)h; t=-5.807, P<0.05]. Three cases suffered abdominal distention, diarrhea in EEN group and 2 cases in PN group. The length of postoperative hospital stay was (18±12)d in EEN group and was (20±14)d in PN group, there was no significant difference between two groups (t=-0.625, P>0.05). The median of total hospitalization cost in EEN group was significantly less than that in PN group [53(45-72) thousand yuan vs. 59(51-79) thousand yuan; Z=-2.34, P<0.05].

Conclusions

Early-stage enteral nutritional support is useful for the recovery of gastrointestinal function of HCC patients after hemihepatectomy and it can also reduce the hospitalization cost.

表1 肠内营养组和静脉营养组患者术后肝功能的比较(±s
[1]
Uchiyama K,Ueno M,Ozawa S. Risk factors for postoperative infectious complications after hepatectomy. J Hepatobiliary Pancreat Sci, 2011, 18(1): 67-73.
[2]
中华人民共和国卫生部(卫办医政发[2011]121号).原发性肝癌诊疗规范(2011年版).临床肿瘤学杂志, 2011, 16(10): 929-946.
[3]
汤钊猷.肝癌临床研究的展望.中国现代普通外科进展, 2009, 12(4): 277-278.
[4]
Llovet JM,Ricci S,Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4): 378-390.
[5]
Cheng AL,Kang YK,Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009, 10(1): 25-34.
[6]
Gustafson JD,Fox JP,Ouellette JR, et al. Open versus laparoscopic liver resection: looking beyond the immediate postoperative period. Surg Endosc, 2012, 26(2): 468-472.
[7]
Viganò L,Tayar C,Laurent A, et al. Laparoscopic liver resection: a systematic review. J Hepatobiliary Pancreat Surg, 2009, 16(4): 410-421.
[8]
Zhou Y,Sui C,Li B, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review. World J Surg Oncol, 2010, 8: 55-65.
[9]
Wu CC,Cheng SB,Yeh DC, et al. Second and third hepatectomies for recurrent hepatocellular carcinoma are justified. Br J Surg, 2009, 96(9): 1049-1057.
[10]
樊嘉,王征.原发性肝癌的手术切除.中华外科杂志, 2010, 48(3): 167-168.
[11]
吕毅,张谞丰.肝细胞肝癌的多学科协作组概念及其实践[J/CD].中华肝脏外科手术学电子杂志, 2013, 2(1): 1-3.
[12]
Okabayashi T,Iyoki M,Sugimoto T, et al. Oral supplementation with carbohydrate- and branched-chain amino acid-enriched nutrients improves postoperative quality of life in patients undergoing hepatic resection. Amino Acids, 2011, 40(4): 1213-1220.
[13]
黎介寿.肠内营养——外科临床营养支持的首选途径.中国实用外科杂志, 2003, 10(3): 67.
[14]
王新颖,牛程麟,章黎,等.肠内营养对肝功能障碍患者腹部手术后肝功能及炎性反应的改善.中华胃肠外科杂志, 2011, 14(5): 336-339.
[15]
秦环龙,杨俊.外科手术后肠内营养的时机、途径和制剂选择.中国实用外科杂志, 2008, 28(1): 79-80.
[16]
黎介寿.临床营养支持的发展趋势.肠外与肠内营养, 2010, 17(1): 1-4.
[17]
韦军民.欧美外科营养指南解读.中国实用外科杂志, 2012, 32(2): 107-109.
[1] 王莹莹, 刘莉, 吕瑞兆, 柳洁, 白晓明, 井郁陌. 下腔静脉变异度为指导的围手术期容量管理在腹腔镜肝切除术中的临床应用[J]. 中华普通外科学文献(电子版), 2022, 16(03): 194-198.
[2] 顾竹劼, 胡双双, 师小伟, 马钰, 陆敏敏, 汪建胜. 老年肝癌合并肝硬化患者围手术期不同液体管理在腹腔镜肝切除术中的对比研究[J]. 中华普通外科学文献(电子版), 2022, 16(03): 199-204.
[3] 周保富, 吴乐乐, 李永红, 胡世超. 肝切除术中不同断肝方式治疗多病灶原发性肝癌的临床效果研究[J]. 中华普通外科学文献(电子版), 2022, 16(03): 205-209.
[4] 刘贤, 兰春斌, 胥彬, 徐竹林, 宋正宇. 肝切除术围手术期症状性静脉血栓栓塞症风险评估模型的建立及验证[J]. 中华普外科手术学杂志(电子版), 2022, 16(03): 319-322.
[5] 张安清, 东爱华, 李红霞, 李爱华. 三种肝血流阻断技术在腹腔镜下肝切除术中的对比研究[J]. 中华普外科手术学杂志(电子版), 2022, 16(03): 323-326.
[6] 陈一帆, 王晨晨, 卢杏生. 肝内胆管导管内乳头状瘤恶变伴门静脉及胆道变异一例并文献复习[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 299-303.
[7] 江哲龙, 魏志鸿, 杜俊杰, 江艺, 吕立志, 杨芳. FOXC2对肝癌肝移植患者预后的影响[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 309-314.
[8] 熊培尧, 唐雨豪, 杨子良, 朱应钦, 王骏成, 徐立. 小鼠VETC(+)肝癌模型构建及索拉非尼对VETC结构的影响[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 315-319.
[9] 江蜜, 柴楚星, 张树华, 唐勇, 胡青钢, 万赤丹, 熊俊. 微波消融联合手术切除治疗巨大肝血管瘤一例[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 320-322.
[10] 阙清扬, 余炯杰, 凌孙彬, 徐骁. 免疫治疗在肝癌肝移植降期治疗中的应用及前景[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 221-224.
[11] 陈泰安, 熊永福, 徐建, 李强, 杨刚, 李敬东. 复杂肝癌腹腔镜肝切除的应用及挑战[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 239-243.
[12] 周陈杰, 王杰钦, 张健民, 冯磊, 傅超毅, 廖晖, 徐小平, 高毅. 浅谈腹腔镜解剖性肝切除手术入路和解剖标志[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 244-247.
[13] 苟晓雪, 王明达, 薛军, 史鸿云, 张新, 杨田. 立体定向放射治疗在肝细胞癌合并门静脉癌栓中的应用[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 248-251.
[14] 谢静, 毛先海, 杨建辉, 段小辉, 田朕安, 张雄, 高绪照. 再次肝切除与腹腔镜微波消融治疗复发性小肝癌临床疗效比较[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 258-262.
[15] 卢文峰, 付雍, 阎凯, 袁建勇, 陈佩钦, 张海斌. 术后预防性TACE对肝内胆管细胞癌患者预后的影响[J]. 中华肝脏外科手术学电子杂志, 2022, 11(03): 268-272.
阅读次数
全文


摘要